MedTrace Logo

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

NCT01293487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.

Conditions

Interventions

BIOLOGICAL

RN564

Intravenous, single dose with experimental dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-01
Primary Completion
2012-05-24
Completion
2012-05-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01293487 on ClinicalTrials.gov